A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced/Metastatic Urothelial Carcinoma
Phase: Phase III clinical trials
Principal Investigator: Dott.ssa Guadalupi Valentina
Main Facility: Oncologia Medica Genitourinaria
Drug: Sacituzumab Tirumotecan (MK-2870) vs Investigator’s Choice of Non-platinum Chemotherapy
Pathologies: Urological cancers (kidney, bladder, urinary tract, others)
Locally advanced/metastatic urothelial carcinoma following treatment with PD-(L)1 inhibitor, platinum-based chemotherapy, and enfortumab vedotin (or disitamab vedotin in China).
Each participant will participate in the study for approximately 2 years from the time the participant provides documented informed consent through the final protocol-specified contact. After a screening period of up to 28 days, each participant will be receiving assigned study intervention for approximately 6 months, though there is no maximum duration of exposure for study medication and treatment intervention will continue until one of the reasons for discontinuation of intervention is met (Section 7.1). After the end of treatment, each participant will be followed for survival for an estimated additional 1 year. After screening, each participant will be assigned to receive study intervention until one of the conditions for discontinuation of study intervention is met. Participants will be followed with posttreatment follow-up imaging for disease status until any of the conditions for discontinuation of imaging are met. After the end of treatment, each participant will be followed for the occurrence of AEs, SAEs, and other reportable safety events. In addition, all participants will be followed for overall survival until death, withdrawal of consent, the end of the study, or enrollment into an extension study (if applicable).
Last update: 09/06/2026